STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health. Confidential tips can be sent on Signal at lizzylaw.53.In a win for peptide proponents and for health secretary Robert F. Kennedy Jr., an advisory panel to the Food and Drug Administration recommended on Thursday that compounding pharmacies be allowed to manufacture the drugs BPC-157 and KPV. The FDA panel will vote on two other peptides, TB-500 and MOTS-c, later on Thursday afternoon, and on additional compounds on Friday. The votes are not binding, and the FDA will ultimately decide whether to lift current restrictions on these peptides and make them more easily accessible to people who’ve been turning to the little-researched but highly popular drugs to improve their health. It’s unusual for the FDA to go against the recommendations of the Pharmacy Compounding Advisory Committee, or PCAC, but it has happened at least once before. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe